Skip to main content
Erschienen in: Rheumatology International 8/2015

01.08.2015 | Original Article - Observational Research

High variability in glucocorticoid starting doses in patients with rheumatoid arthritis: observational data from an early arthritis cohort

verfasst von: Katinka Albrecht, Johanna Callhoff, Matthias Schneider, Angela Zink

Erschienen in: Rheumatology International | Ausgabe 8/2015

Einloggen, um Zugang zu erhalten

Abstract

To evaluate initial glucocorticoid (GC) therapy in patients with rheumatoid arthritis (RA). Six hundred sixty-nine patients with early RA were followed for 2 years in the multicenter “Course And Prognosis of Early Arthritis” cohort. Treatment was applied according to routine care. Assessments included disease activity (DAS28), disability Hannover Functional Status Questionnaire (FFbH), and treatment details. Mixed models, ANCOVA, and logistic regression models were used for statistical analysis. In total, 518 patients (77 %) received oral GCs at baseline; 20 % received a low dose (<7.5 mg prednisolone/day), 22 % received a moderate (7.5–19 mg), and 35 % received a high dose (≥20 mg). In a multivariate logistic regression analysis, higher DAS28 values (OR 1.3) were associated with the use of higher GC doses at baseline (p < 0.001). After adjusting for age, sex, and baseline DAS28 and DMARDs, the patients who started with high-dose GCs had a greater improvement in DAS28 (month 3) and FFbH (month 6, p < 0.001 each). At 2 years, the mean DAS28 remission rates and FFbH values were similar. In all GC groups, the mean dose was tapered to 4 mg/day within 6 months. The reported comorbidities were not increased in patients with high-dose GC therapy. Starting treatment with high-dose GCs led to a better clinical response within 3 to 6 months compared to starting patients on lower dosages. Irrespective of the starting approach, rheumatologists tapered GCs down to a low dose within 6 months. With this strategy, clinical outcomes at 2 years did not differ relevantly.
Literatur
1.
Zurück zum Zitat Smolen JS, Aletaha D, Machold KP (2005) Therapeutic strategies in early rheumatoid arthritis. Best Pract Res Clin Rheumatol 19(1):163–177PubMedCrossRef Smolen JS, Aletaha D, Machold KP (2005) Therapeutic strategies in early rheumatoid arthritis. Best Pract Res Clin Rheumatol 19(1):163–177PubMedCrossRef
2.
Zurück zum Zitat van Nies JA, Krabben A, Schoones JW, Huizinga TW, Kloppenburg M, van der Helm-van Mil AH (2014) What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review. Ann Rheum Dis 73(5):861–870PubMedCrossRef van Nies JA, Krabben A, Schoones JW, Huizinga TW, Kloppenburg M, van der Helm-van Mil AH (2014) What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review. Ann Rheum Dis 73(5):861–870PubMedCrossRef
3.
Zurück zum Zitat Smolen JS, Landewe R, Breedveld FC et al (2014) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73(3):492–509PubMedCentralPubMedCrossRef Smolen JS, Landewe R, Breedveld FC et al (2014) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73(3):492–509PubMedCentralPubMedCrossRef
4.
Zurück zum Zitat Albrecht K, Kruger K, Wollenhaupt J et al (2014) German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. Rheumatol Int 34(1):1–9PubMedCrossRef Albrecht K, Kruger K, Wollenhaupt J et al (2014) German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. Rheumatol Int 34(1):1–9PubMedCrossRef
5.
Zurück zum Zitat Singh JA, Furst DE, Bharat A et al (2012) 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 64(5):625–639CrossRef Singh JA, Furst DE, Bharat A et al (2012) 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 64(5):625–639CrossRef
7.
Zurück zum Zitat Duru N, van der Goes MC, Jacobs JW et al (2013) EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 72(12):1905–1913PubMedCrossRef Duru N, van der Goes MC, Jacobs JW et al (2013) EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 72(12):1905–1913PubMedCrossRef
8.
Zurück zum Zitat Gaujoux-Viala C, Nam J, Ramiro S et al (2014) Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 73(3):510–515PubMedCentralPubMedCrossRef Gaujoux-Viala C, Nam J, Ramiro S et al (2014) Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 73(3):510–515PubMedCentralPubMedCrossRef
9.
Zurück zum Zitat Rau R (2014) Glucocorticoid treatment in rheumatoid arthritis. Expert Opin Pharmacother 15(11):1575–1583PubMedCrossRef Rau R (2014) Glucocorticoid treatment in rheumatoid arthritis. Expert Opin Pharmacother 15(11):1575–1583PubMedCrossRef
10.
Zurück zum Zitat Boers M, van Tuyl PJ, van den Broek M, Kostense PJ, Allaart CF (2013) Meta-analysis suggests that intensive non-biological combination therapy with step-down prednisolone (COBRA strategy) may also ‘disconnect’ disease activity and damage in rheumatoid arthritis. Ann Rheum Dis 72(3):406–409PubMedCrossRef Boers M, van Tuyl PJ, van den Broek M, Kostense PJ, Allaart CF (2013) Meta-analysis suggests that intensive non-biological combination therapy with step-down prednisolone (COBRA strategy) may also ‘disconnect’ disease activity and damage in rheumatoid arthritis. Ann Rheum Dis 72(3):406–409PubMedCrossRef
11.
Zurück zum Zitat Montecucco C, Todoerti M, Sakellariou G, Scire CA, Caporali R (2012) Low-dose oral prednisone improves clinical and ultrasonographic remission rates in early rheumatoid arthritis: results of a 12-month open-label randomised study. Arthritis Res Ther 14(3):R112PubMedCentralPubMedCrossRef Montecucco C, Todoerti M, Sakellariou G, Scire CA, Caporali R (2012) Low-dose oral prednisone improves clinical and ultrasonographic remission rates in early rheumatoid arthritis: results of a 12-month open-label randomised study. Arthritis Res Ther 14(3):R112PubMedCentralPubMedCrossRef
12.
Zurück zum Zitat Svensson B, Hafstrom I (2011) Effects on joint destruction and remission, bone turnover and lack of influence on atherogenesis: a review of the BARFOT low-dose prednisolone studies on patients with early RA. Clin Exp Rheumatol 29(5 Suppl 68):S63–S67PubMed Svensson B, Hafstrom I (2011) Effects on joint destruction and remission, bone turnover and lack of influence on atherogenesis: a review of the BARFOT low-dose prednisolone studies on patients with early RA. Clin Exp Rheumatol 29(5 Suppl 68):S63–S67PubMed
13.
Zurück zum Zitat Nam JL, Villeneuve E, Hensor EM et al (2014) Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study). Ann Rheum Dis 73(1):75–85PubMedCrossRef Nam JL, Villeneuve E, Hensor EM et al (2014) Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study). Ann Rheum Dis 73(1):75–85PubMedCrossRef
14.
Zurück zum Zitat Hetland ML, Horslev-Petersen K (2012) The CIMESTRA study: intra-articular glucocorticosteroids and synthetic DMARDs in a treat-to-target strategy in early rheumatoid arthritis. Clin Exp Rheumatol 30(4 Suppl 73):S44–S49PubMed Hetland ML, Horslev-Petersen K (2012) The CIMESTRA study: intra-articular glucocorticosteroids and synthetic DMARDs in a treat-to-target strategy in early rheumatoid arthritis. Clin Exp Rheumatol 30(4 Suppl 73):S44–S49PubMed
15.
Zurück zum Zitat de Jong PH, Hazes JM, Barendregt PJ et al (2013) Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial. Ann Rheum Dis 72(1):72–78PubMedCrossRef de Jong PH, Hazes JM, Barendregt PJ et al (2013) Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial. Ann Rheum Dis 72(1):72–78PubMedCrossRef
16.
Zurück zum Zitat Bakker MF, Jacobs JW, Welsing PM et al (2012) Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med 156(5):329–339PubMedCrossRef Bakker MF, Jacobs JW, Welsing PM et al (2012) Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med 156(5):329–339PubMedCrossRef
17.
Zurück zum Zitat Gossec L, Paternotte S, Aanerud GJ et al (2011) Finalisation and validation of the rheumatoid arthritis impact of disease score, a patient-derived composite measure of impact of rheumatoid arthritis: a EULAR initiative. Ann Rheum Dis 70(6):935–942PubMedCrossRef Gossec L, Paternotte S, Aanerud GJ et al (2011) Finalisation and validation of the rheumatoid arthritis impact of disease score, a patient-derived composite measure of impact of rheumatoid arthritis: a EULAR initiative. Ann Rheum Dis 70(6):935–942PubMedCrossRef
18.
Zurück zum Zitat Lautenschlaeger J, Mau W, Kohlmann T et al (1997) [Comparative evaluation of a German version of the Health Assessment Questionnaire and the Hannover Functional Capacity Questionnaire] German. Z Rheumatol 56(3):144–155CrossRef Lautenschlaeger J, Mau W, Kohlmann T et al (1997) [Comparative evaluation of a German version of the Health Assessment Questionnaire and the Hannover Functional Capacity Questionnaire] German. Z Rheumatol 56(3):144–155CrossRef
19.
Zurück zum Zitat Boyd TA, Bonner A, Thorne C et al (2013) The relationship between function and disease activity as measured by the HAQ and DAS28 varies over time and by Rheumatoid factor status in early inflammatory arthritis (EIA). Results from the CATCH Cohort. Open Rheumatol J 7:58–63PubMedCentralPubMedCrossRef Boyd TA, Bonner A, Thorne C et al (2013) The relationship between function and disease activity as measured by the HAQ and DAS28 varies over time and by Rheumatoid factor status in early inflammatory arthritis (EIA). Results from the CATCH Cohort. Open Rheumatol J 7:58–63PubMedCentralPubMedCrossRef
20.
Zurück zum Zitat Combe B, Rincheval N, Benessiano J et al (2013) Five-year favorable outcome of patients with early rheumatoid arthritis in the 2000s: data from the ESPOIR cohort. J Rheumatol 40(10):1650–1657PubMedCrossRef Combe B, Rincheval N, Benessiano J et al (2013) Five-year favorable outcome of patients with early rheumatoid arthritis in the 2000s: data from the ESPOIR cohort. J Rheumatol 40(10):1650–1657PubMedCrossRef
21.
Zurück zum Zitat Svensson B, Andersson ML, Bala SV, Forslind K, Hafstrom I (2013) Long-term sustained remission in a cohort study of patients with rheumatoid arthritis: choice of remission criteria. BMJ Open 3(9):e003554PubMedCentralPubMedCrossRef Svensson B, Andersson ML, Bala SV, Forslind K, Hafstrom I (2013) Long-term sustained remission in a cohort study of patients with rheumatoid arthritis: choice of remission criteria. BMJ Open 3(9):e003554PubMedCentralPubMedCrossRef
22.
Zurück zum Zitat McKeown E, Bykerk VP, De Leon F et al (2012) Quality assurance study of the use of preventative therapies in glucocorticoid-induced osteoporosis in early inflammatory arthritis: results from the CATCH cohort. Rheumatology (Oxford) 51(9):1662–1669CrossRef McKeown E, Bykerk VP, De Leon F et al (2012) Quality assurance study of the use of preventative therapies in glucocorticoid-induced osteoporosis in early inflammatory arthritis: results from the CATCH cohort. Rheumatology (Oxford) 51(9):1662–1669CrossRef
23.
Zurück zum Zitat Cardiel MH, Pons-Estel BA, Sacnun MP et al (2012) Treatment of early rheumatoid arthritis in a multinational inception cohort of Latin American patients: the GLADAR experience. J Clin Rheumatol 18(7):327–335PubMedCrossRef Cardiel MH, Pons-Estel BA, Sacnun MP et al (2012) Treatment of early rheumatoid arthritis in a multinational inception cohort of Latin American patients: the GLADAR experience. J Clin Rheumatol 18(7):327–335PubMedCrossRef
24.
Zurück zum Zitat Wassenberg S, Rau R, Zeidler H (2011) A dose of only 5 mg prednisolone daily retards radiographic progression in early rheumatoid arthritis-the low-dose prednisolone trial. Clin Exp Rheumatol 29(5 Suppl 68):S68–S72PubMed Wassenberg S, Rau R, Zeidler H (2011) A dose of only 5 mg prednisolone daily retards radiographic progression in early rheumatoid arthritis-the low-dose prednisolone trial. Clin Exp Rheumatol 29(5 Suppl 68):S68–S72PubMed
25.
Zurück zum Zitat Buttgereit F, Mehta D, Kirwan J et al (2013) Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). Ann Rheum Dis 72(2):204–210PubMedCentralPubMedCrossRef Buttgereit F, Mehta D, Kirwan J et al (2013) Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). Ann Rheum Dis 72(2):204–210PubMedCentralPubMedCrossRef
Metadaten
Titel
High variability in glucocorticoid starting doses in patients with rheumatoid arthritis: observational data from an early arthritis cohort
verfasst von
Katinka Albrecht
Johanna Callhoff
Matthias Schneider
Angela Zink
Publikationsdatum
01.08.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Rheumatology International / Ausgabe 8/2015
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-015-3229-x

Weitere Artikel der Ausgabe 8/2015

Rheumatology International 8/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.